Clinical Trials · NCT00425256
Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Palatin Technologies, Inc
- Enrollment
- 0
- Start date
- Feb 2006
- Locations
- 20 sites, United States
- Primary endpoint
- Study in Sexual Arousal Disorder